Table 3.

Prognostic factors on response and regrowth

		Treatment response		Local regrowth
n	HR	95% CI	p	HR	95% CI	p
PS	0	66	Ref		0.15	Ref		0.83
	1	73	0.43	0.20–0.95		1.30	0.39–4.29
	2	41	0.93	0.40–2.13		2.09	0.59–7.35
	3	7	0.80	0.14–4.46		0.00	0.00
Not known	13	1.71	0.51–5.72	1.02	0.11–9.49
Age group	<70	72	Ref		0.26	Ref		0.46
	70–79	63	0.48	0.22–1.02		1.41	0.41–4.87
	80–89	57	0.60	0.60–2.78		1.58	0.46–5.46
≥90	8	0.00	0.00	4.47	0.71–28.13
Tumour stage	cT1	21	Ref		0.20	Ref		0.90
	cT2	89	1.23	0.37–4.08		0.59	0.14–2.46
	cT3	87	2.35	0.73–7.61		0.61	0.15–2.52
cT4	3	2.12	0.15–29.66	0.00	0.00
Nodal stage	Negative	125	Ref		0.59	Ref		0.63
	Positive	74	1.344	0.72–2.62		1.59	0.61–4.12
Not known	1	0.00	0.00	0.00	0.00
Distance from anal verge	<7 cm	144	Ref		0.88	Ref		0.91
	7–11 cm	47	1.07	0.52–2.20		0.46	1.47–0.53
	>11 cm	2	0.00	0.00		0.00	0.00
Not known	7	0.42	0.05–3.59	0.00	0.00
Tumour size	≤3 cm	107	Ref		0.28	Ref		0.50
	>3 cm	65	1.56	0.79–3.11		0.80	0.29–2.26
Not known	28	1.82	0.75–4.45	0.29	0.04–2.36
Treatment method	Chemoradiation	127	Ref		0.20	Ref		0.50
	EBRT alone	56	0.51	0.24–1.01		1.03	0.34–3.13
CBX alone	17	0.64	0.20–2.10	2.26	0.56–9.09
Papillion total dose	≤90 Gy	162			0.40	Ref		0.20
>90 Gy	32	0.68	0.28–1.67	2.04	0.68–6.12

CXB, contact X-ray brachytherapy; EBRT, external beam radiotherapy; PS, performance status.